Logo image of RN.MI

RISANAMENTO SPA (RN.MI) Stock Fundamental Analysis

BIT:RN - Euronext Milan - IT0001402269 - Common Stock - Currency: EUR

0.0282  +0 (+3.3%)

Fundamental Rating

1

Overall RN gets a fundamental rating of 1 out of 10. We evaluated RN against 69 industry peers in the Real Estate Management & Development industry. RN has a bad profitability rating. Also its financial health evaluation is rather negative. RN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RN had negative earnings in the past year.
In the past year RN has reported a negative cash flow from operations.
In multiple years RN reported negative net income over the last 5 years.
In the past 5 years RN reported 4 times negative operating cash flow.
RN.MI Yearly Net Income VS EBIT VS OCF VS FCFRN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -20.85%, RN is not doing good in the industry: 76.00% of the companies in the same industry are doing better.
RN has a Return On Equity of -133.24%. This is in the lower half of the industry: RN underperforms 77.33% of its industry peers.
Industry RankSector Rank
ROA -20.85%
ROE -133.24%
ROIC N/A
ROA(3y)-1.65%
ROA(5y)-1.6%
ROE(3y)-44.65%
ROE(5y)-30.52%
ROIC(3y)N/A
ROIC(5y)N/A
RN.MI Yearly ROA, ROE, ROICRN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

RN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RN.MI Yearly Profit, Operating, Gross MarginsRN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K

More info and screens

3

2. Health

2.1 Basic Checks

RN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RN remains at a similar level compared to 1 year ago.
Compared to 5 years ago, RN has about the same amount of shares outstanding.
The debt/assets ratio for RN has been reduced compared to a year ago.
RN.MI Yearly Shares OutstandingRN.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B
RN.MI Yearly Total Debt VS Total AssetsRN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.66, we must say that RN is in the distress zone and has some risk of bankruptcy.
RN's Altman-Z score of -0.66 is on the low side compared to the rest of the industry. RN is outperformed by 70.67% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that RN is not too dependend on debt financing.
The Debt to Equity ratio of RN (0.00) is better than 97.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.66
ROIC/WACCN/A
WACC1.52%
RN.MI Yearly LT Debt VS Equity VS FCFRN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 1.86 indicates that RN should not have too much problems paying its short term obligations.
With a decent Current ratio value of 1.86, RN is doing good in the industry, outperforming 76.00% of the companies in the same industry.
A Quick Ratio of 0.58 indicates that RN may have some problems paying its short term obligations.
RN has a Quick ratio of 0.58. This is comparable to the rest of the industry: RN outperforms 44.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 0.58
RN.MI Yearly Current Assets VS Current LiabilitesRN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for RN have decreased strongly by -118.82% in the last year.
Looking at the last year, RN shows a very negative growth in Revenue. The Revenue has decreased by -98.47% in the last year.
Measured over the past years, RN shows a very strong growth in Revenue. The Revenue has been growing by 238.97% on average per year.
EPS 1Y (TTM)-118.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)-98.47%
Revenue growth 3Y1082.73%
Revenue growth 5Y238.97%
Sales Q2Q%-36.84%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RN.MI Yearly Revenue VS EstimatesRN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M
RN.MI Yearly EPS VS EstimatesRN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RN.MI Price Earnings VS Forward Price EarningsRN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RN.MI Per share dataRN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RISANAMENTO SPA

BIT:RN (3/6/2025, 7:00:00 PM)

0.0282

+0 (+3.3%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)02-13 2025-02-13
Earnings (Next)04-30 2025-04-30
Inst Owners49.05%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap50.78M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.66
P/FCF N/A
P/OCF N/A
P/B 2.02
P/tB 2.02
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.85%
ROE -133.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1.65%
ROA(5y)-1.6%
ROE(3y)-44.65%
ROE(5y)-30.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 82.08%
Cap/Sales 1.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 0.58
Altman-Z -0.66
F-Score1
WACC1.52%
ROIC/WACCN/A
Cap/Depr(3y)6.41%
Cap/Depr(5y)9.96%
Cap/Sales(3y)11.69%
Cap/Sales(5y)16.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-118.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.47%
Revenue growth 3Y1082.73%
Revenue growth 5Y238.97%
Sales Q2Q%-36.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2127.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.27%
OCF growth 3YN/A
OCF growth 5YN/A